PR Newswire Clinical TrialsOriginal article
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
Patent ExpiryATR-12Positive
AI Analysis
Summary
Azitra, Inc. announced a new U.S. patent providing broad protections for ATR-12, an engineered S. epidermidis strain expressing human LEKTI protein, currently in Phase 1b trials for Netherton syndrome treatment.
Clinical Trial Data
Phase
1b
Outcome Details
New U.S. patent awarded providing broad protections for ATR-12 program
Importance:3/10
Sentiment:
0.30
patentATR-12Netherton syndromePhase 1bintellectual property
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on May 6, 2026 12:00 PM